Latest Breaking News On - மருத்துவமனை தொற்று - Page 11 : comparemela.com

®, the only FDA-cleared device platform indicated to reduce blood culture contamination 1 – today announced that unprecedented Steripath clinical study results were presented to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). Lucy S. Tompkins, MD, Ph.D., a professor and infectious diseases, microbiology and epidemiology expert at Stanford Health Care, presented Steripath ® Gen2 Initial Specimen Diversion Device ® (ISDD ®) phase-one study results at the PACCARB meeting in Washington, DC demonstrating unmatched reductions to blood culture contamination and false-positive central line-associated bloodstream infection (CLABSI) rates. What was even more clinically significant is that a 0.0% contamination rate and 0.0% false-positive CLABSI rate were maintained across over 11,000 blood cultures when Steripath was used throughout the course of the 10-month total trial period, continued Dr. Tompkins

Steripath-gen
Greg-bullington
Us-department-of-health
Human-services
Stanford-health-care
Eliminating-blood-culture-contamination
Specimen-diversion-device
Initial-specimen-diversion
Steripath-micro
Medical-technologies
Initial-specimen-diversion-technique
Emergency-nursing